Ser62
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser62  -  Cot (human)

Site Information
QNDERSKsLLLSGQE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2868603

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 ) , mutation of modification site ( 2 ) , phospho-antibody ( 2 ) , western blotting ( 2 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 2 ) , breast ( 1 ) , Sf21 ( 2 )

Upstream Regulation
Treatments:
serum ( 2 )

Downstream Regulation
Effects of modification on Cot:
enzymatic activity, induced ( 2 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Stafford MJ, Morrice NA, Peggie MW, Cohen P (2006) Interleukin-1 stimulated activation of the COT catalytic subunit through the phosphorylation of Thr290 and Ser62. FEBS Lett 580, 4010-4
16806191   Curated Info